Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
NCT02519842 · Merck Sharp & Dohme LLC · PHASE3 · terminated · last registry update 2019-03-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-18Results posted on the registry: University of California, San Diego, Ranolazine + Placebo (NCT01505179)
- 2019-12-17Phase 3 first posted: Consorzio Oncotech, Netupitant/Palonosetron + Dexamethasone (NCT04201769)
- 2019-12-09Also stopped (terminated): Joseph Ma, Netupitant and Palonosetron (NCT03008213)
- 2019-10-28Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT04140695)
- 2019-10-22Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets + Matching Placebo Tablets (NCT03282591)
- 2019-10-09Also stopped (terminated): Sunnybrook Health Sciences Centre, Aprepitant + Granisetron (NCT01183481)
- 2019-09-27Results posted on the registry: Spanish Breast Cancer Research Group, Aprepitant (NCT01298193)
- 2019-09-03Phase 3 first posted: CR-CSSS Champlain-Charles-Le Moyne, Zyprexa® (OLANZapine 5MG) + Emend® (Aprepitant) (NCT04075955)
- 2019-07-22Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT04028492)
- 2019-07-02Results posted on the registry: Jean Yuh Tang, VPD-737 (NCT02654483)
- 2019-06-12Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets + Matching Placebo Tablets (NCT03343639)
- 2019-05-22Also stopped (withdrawn): Costantine Albany, Rolapitant + Palonosetron (NCT03960151)
- 2019-05-09Results posted on the registry: Joseph Ma, Netupitant and Palonosetron (NCT03008213)
- 2019-05-08Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Aprepitant + Placebo (NCT01149369)
- 2019-03-15Phase 3 first posted: Mahidol University, aprepitant + olanzapine 10 mg (NCT03876938)
- 2019-03-12Results posted on the registry: Acacia Pharma Ltd, Ondansetron + Placebo (NCT01857232)
- 2019-03-07Results posted on the registry: Vanderbilt University, Propofol + Sevoflurane (NCT02625181)
- 2019-03-05Results posted on the registry: Vyne Therapeutics Inc., Serlopitant High Dose + Placebo Oral Tablet (NCT02975206)
- 2019-01-18Phase 3 first posted: University Hospital, Brest, Aprepitant 80 mg + Hydroxyzine 25mg (NCT03808805)
- 2018-10-30Results posted on the registry: Dartmouth-Hitchcock Medical Center, Aprepitant + Placebo (NCT01854177)
- 2018-09-25Also stopped (terminated): Merck Sharp & Dohme LLC, Experimental: aprepitant + Experimental: fosaprepitant (NCT00818259)
- 2018-09-19Phase 3 first posted: Vyne Therapeutics Inc., 5mg Serlopitant Tablets + Placebo Tablets (NCT03677401)
- 2018-09-17Phase 3 first posted: Sun Yat-sen University, Aprepitant + Palonosetron (NCT03674294)
- 2018-09-12Phase 3 first posted: Christina Ruhlmann, Akynzeo + Dexamethasone (NCT03668639)
- 2018-08-27Also stopped (terminated): Merck Sharp & Dohme LLC, Fosaprepitant dimeglumine + 5-HT3 RA (NCT01405924)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision